68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.

PHASE4RecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

September 4, 2019

Primary Completion Date

December 31, 2038

Study Completion Date

December 31, 2038

Conditions
CNS TumorsMeningiomaEsthesioneuroblastomaHemangioblastomaMedulloblastomaParagangliomaPituitary Adenoma
Interventions
DIAGNOSTIC_TEST

Ga68-DOTATATE-PET/MRI

"In patients with meningioma who are undergoing surgical planning, subjects will undergo a PET scan at the time of their pretreatment or preoperative standard of care MRI exam, prior to surgery performed for research purposes. Instead of the standard of care MRI exam, subjects will undergo a dedicated hybrid Gallium-68-DOTATATE PET/MRI.There will be up to two follow-up with Ga68-DOTATATE PET/MRI scans performed as standard of care.~In patients with SSTR-positive CNS tumors that are non-meningioma, MRI is often performed to assess extent of disease. Subjects may be asked to undergo a PET scan for research purposes at the time of their standard of care MRI. Instead of the standard of care MRI exam, they may be asked to undergo a dedicated hybrid Gallium-68-DOTATATE PET/MRI."

Trial Locations (1)

10065

RECRUITING

Weill Cornell Medicine, New York

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

Weill Medical College of Cornell University

OTHER